Media and Press

iMedicor Signs Agreement With Access Pharmaceuticals For the North American Commercial Launch of MuGard

Targeted Messages will be Delivered to over 200,000 Specialty Medical Practices

NANUET, NEW YORK, October 6, 2009 -- iMedicor (OTCBB: VMCI) today announced it has signed an agreement with Dallas-based Access Pharmaceuticals (OTCBB: ACCP) for the North American commercial launch of MuGard, its FDA-approved oral wound rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.

In return for its online marketing services, iMedicor will receive a monthly fee, click-through revenue and a royalty of up to five percent of all product sales generated through iMedicor's portal. Business Week recently noted that MuGard has an estimated worldwide market in excess of $5 billion. The program will deliver targeted online marketing messages to 216,000 specialty medical practices across the country via the iMedicor portal.

"iMedicor's powerful web portal presents us with an invaluable and low-cost option to reach the exact physician demographic we seek inour marketing efforts," said Access president and chief executive, Jeffrey B. Davis. "We look forward to working with iMedicor to deliver information on MuGard™ to the over 200,000 specialty practices in the U.S. that treat cancer patients with this painful radiation and chemotherapy side effect."

MuGard is used prophylactically for patients undergoing chemotherapy and radiation therapy for the management of oral mucositis, a painful inflammation of the mouth's mucous membranes. This side affect afflicts approximately 80 percent of cancer patients receiving radiation therapy and 40 percent of cancer patients receiving chemotherapy. It is currently marketed in the United Kingdom, Germany, Italy, Norway and Greece.

"We are very pleased to be aligned with Access Pharmaceuticals in this effort," said iMedicor chief executive Fred Zolla. "By placing targeted messages into the hands of specific physicians and their staff at the point of care, we are confident that Access will achieve far greater ROIs on their marketing efforts." Additional marketing agreements with pharmaceutical companies, representing significant revenue potential, are expected to be completed in the near future, he added.

About iMedicor:

iMedicor is the only HIPAA-compliant solution for interoperable health information transfer that is offered at no cost to physicians, healthcare providers and patients. The iMedicor portal enables disparate EMR (electronic medical record) systems to communicate, collaborate and exchange records in real time; pharmaceutical companies to deliver customized educational marketing programs to more than 730,000 healthcare providers nationwide in a highly targeted, non-intrusive manner; and allows a medical practice to send and receive medical records, files and images. For more information on iMedicor visit www.imedicor.com.

About Access Pharmaceuticals, Inc:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. In addition to MuGard™ Access' products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer and also under study for its potential role in combination with other pharmaceuticals in the treatment of hepatocellular carcinoma (a form of liver cancer), and pancreatic cancer. The Company's pipeline also includes: Cobalamin™- mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. More information on Access Pharmaceuticals is available at www.accesspharma.com.

The statements contained herein, other than historical information, are or may be deemed to be forward-looking statements and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. These factors, risks, and uncertainties include market acceptance of iMedicor’s products and services; the nonexclusive and terminable-at-will nature of certain of the company's partnerships and agreements; rapid technological change affecting demand for our products and services; competition from companies providing similar products and services, availability of sufficient financial resources to enable us to expand our operations, as well as other risks detailed from time to time in our filing s with the Securities and Exchange Commission.